about
Phenazepam abuse in Finland: findings from apprehended drivers, post-mortem cases and police confiscationsAn epidemic of fatal 3-methylfentanyl poisoning in EstoniaNewer antidepressants: evaluation of fatal toxicity index and interaction with alcohol based on Finnish postmortem data.Analysis of street drugs in seized material without primary reference standards.Screening for basic drugs in 2-mL urine samples by dual-plate overpressured layer chromatography and comparison with gas chromatography-mass spectrometry.Comparison of product ion spectra obtained by liquid chromatography/triple-quadrupole mass spectrometry for library search.Qualitative screening for basic drugs in autopsy liver samples by dual-plate overpressured layer chromatography.In silico methods for predicting metabolism and mass fragmentation applied to quetiapine in liquid chromatography/time-of-flight mass spectrometry urine drug screening.Matrix effect in the analysis of drugs of abuse from urine with desorption atmospheric pressure photoionization-mass spectrometry (DAPPI-MS) and desorption electrospray ionization-mass spectrometry (DESI-MS).Application of electrospray ionization product ion spectra for identification with atmospheric pressure matrix-assisted laser desorption/ionization mass spectrometry - a case study with seized drugs.Simultaneous identification and quantification of new psychoactive substances in blood by GC-APCI-QTOFMS coupled to nitrogen chemiluminescence detection without authentic reference standards.Development of a GC-APCI-QTOFMS library for new psychoactive substances and comparison to a commercial ESI library.Differentiation of structural isomers in a target drug database by LC/Q-TOFMS using fragmentation prediction.Specific screening method for dextran and hydroxyethyl starch in human urine by size exclusion chromatography-in-source collision-induced dissociation-time-of-flight mass spectrometry.Current use of high-resolution mass spectrometry in drug screening relevant to clinical and forensic toxicology and doping control.Death following ingestion of MDMA (ecstasy) and moclobemide.Interaction of alcohol and drugs in fatal poisonings.Toxicological screening with formula-based metabolite identification by liquid chromatography/time-of-flight mass spectrometry.A high-sensitivity ultra-high performance liquid chromatography/high-resolution time-of-flight mass spectrometry (UHPLC-HR-TOFMS) method for screening synthetic cannabinoids and other drugs of abuse in urine.Isotopic pattern and accurate mass determination in urine drug screening by liquid chromatography/time-of-flight mass spectrometry.Drug concentrations in post-mortem femoral blood compared with therapeutic concentrations in plasmaA general screening method for doping agents in human urine by solid phase extraction and liquid chromatography/time-of-flight mass spectrometry.Profiles of pregabalin and gabapentin abuse by postmortem toxicology.Manganese-enhanced magnetic resonance imaging reveals differential long-term neuroadaptation after methamphetamine and the substituted cathinone 4-methylmethcathinone (mephedrone).Mitochondrial respiratory dysfunction due to the conversion of substituted cathinones to methylbenzamides in SH-SY5Y cells.Keto amphetamine toxicity-focus on the redox reactivity of the cathinone designer drug mephedrone.Comparison between drug screening by immunoassay and ultra-high performance liquid chromatography/high-resolution time-of-flight mass spectrometry in post-mortem urine.Analgesic concentrations of oxycodone--a prospective clinical PK/PD study in patients with laparoscopic cholecystectomy.Concurrent estimation of metabolite concentrations along with parent drug quantification in post-mortem blood.Fatal toxicity index of medicinal drugs based on a comprehensive toxicology database.Polydrug abuse among opioid maintenance treatment patients is related to inadequate dose of maintenance treatment medicine.New psychoactive substances as part of polydrug abuse within opioid maintenance treatment revealed by comprehensive high-resolution mass spectrometric urine drug screening.The effect of banning MDPV on the incidence of MDPV-positive findings among users of illegal drugs and on court decisions in traffic cases in Finland.Patterns of drug abuse among drug users with regular and irregular attendance for treatment as detected by comprehensive UHPLC-HR-TOF-MS.Fatal poisoning in drug addicts in the Nordic countries in 2012.Hydrophilic interaction liquid chromatography and accurate mass measurement for quantification and confirmation of morphine, codeine and their glucuronide conjugates in human urine.Broad-spectrum drug screening of meconium by liquid chromatography with tandem mass spectrometry and time-of-flight mass spectrometry.Headspace in-tube extraction gas chromatography-mass spectrometry for the analysis of hydroxylic methyl-derivatized and volatile organic compounds in blood and urine.Adverse interaction of warfarin and paracetamol: evidence from a post-mortem study.Screening for basic drugs in hair of drug addicts by liquid chromatography/time-of-flight mass spectrometry.
P50
Q28261296-19AAC623-E7A1-4419-B8CF-656366D39B82Q28275032-0FB476EA-5493-457D-BE1F-9E7D15CA4302Q30983846-756A0E67-5FC9-45F9-B79E-071F8E783E90Q31135798-16997141-6E49-4417-8A62-654C26CAA84CQ31147430-2ED2B022-76D3-4670-B0FB-865E4D8EB857Q33203037-1980356D-50DE-407F-97F9-E24272C26C20Q33294677-71D36FFD-E2D7-4C6B-8470-2FCB37946A3AQ33399778-31382099-E053-41D7-A944-11A930F9AE85Q33450985-4CAE6A6D-CBAE-4A0F-B083-CE08EBD82D6DQ33455896-27626E14-6F4F-44F8-A06A-FF59C8409DB4Q33467435-DA631080-ABBA-48F7-91EC-39E2B0E11BC0Q33469491-AB49A222-1B96-40F7-8AA0-CD5528D9D8F0Q33610371-C5DBCBF4-6C3A-4733-BED2-48EBAE115D59Q33849842-E4A42583-47C5-44CD-80F7-96C04F674BFEQ34149545-5FC37C64-D4EC-43CA-9F01-078B49439635Q34179506-206A5E86-29B3-4D42-B5E8-EAEEC6E57225Q34201254-31ED5DE6-6053-476D-B55D-41670D436B52Q34273480-2DB89A65-742C-4904-A2AC-AE3D454F9F64Q34364856-BE5B65E8-4F0C-4948-8E04-A942716D6000Q34500109-2CD2D6FE-DB6B-47AB-8870-FC55CC87FC6BQ34541313-132E66AF-FD57-45AC-AB7E-B2D196734577Q34612389-3466374C-C5D0-4C6D-934E-BF8898D8C031Q34661916-2371F871-4EED-4BDC-B0E1-0639D381644CQ35626948-88763829-B44E-460E-BBB5-DA8697562DC8Q38828261-AD24A707-0CB2-4C7C-A5DB-25B6FCF8AD72Q38986358-7E986552-542D-4581-B9A9-53C2731B2D1BQ39172040-0724D1EF-AD0E-4FB6-AD2C-CD535ACE8758Q39255176-E6708835-9F04-43FE-B0B3-4B3C00E1B345Q39420850-66EBE46F-04C8-4B45-A399-6AB3416C3AC6Q40847928-8B1B3BAC-1F59-4230-BC03-21E4A92F45F3Q40960251-CF9CA9DB-3D98-4404-B6DE-DD5C4E609AD4Q40979436-8848915C-F93C-4E74-B3BF-E4A3AD03E29CQ41126358-266CDBCA-298E-4894-9D47-E1DE92B52267Q41199607-C62775F1-AAB1-4C2B-8B96-6FC1EFB740E4Q41489865-6176D480-02F4-45AF-ACA1-89B72BBF5C5EQ42873528-07EA764B-C899-4274-AB94-08DC79C63548Q42975289-49E1EF45-7EC7-42DC-B058-259C2CD27447Q43091891-D1ED1BDD-4B0B-41F5-AD5F-D809642B9892Q43271666-4001D2D6-70B4-4F41-8E59-87AE976B14CBQ44075359-E9075BF3-AED5-4E43-8ACA-B6A127FBF388
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ilkka Ojanperä
@ast
Ilkka Ojanperä
@en
Ilkka Ojanperä
@es
Ilkka Ojanperä
@sl
type
label
Ilkka Ojanperä
@ast
Ilkka Ojanperä
@en
Ilkka Ojanperä
@es
Ilkka Ojanperä
@sl
prefLabel
Ilkka Ojanperä
@ast
Ilkka Ojanperä
@en
Ilkka Ojanperä
@es
Ilkka Ojanperä
@sl
P106
P21
P31
P496
0000-0001-5790-1473